Silencing of PKG1 expression enhances the efficacy of vemurafenib against melanoma cell

doi:10.12047/j.cjap.5559.2017.071

Abstract

Abstract: Objective: To explore whether targeting phosphoglycerate kinase 1 (PGK1) can enhance the sensitivity of BRAF^V600E mutation melanoma cells to vemurafenib.Methods: The methods of cell biology, molecular biology and pharmacology(MTT assay, Western blot, FCM, Colongenic assay) were used in this study.Results: ① Silencing of PGK1 expression increased the efficacy of vemurafenib in melanoma cells, as evidenced by greater killing in the tumor cells subjected to combined treatment of vemurafenib with siPGK1; ②The mechanism of enhanced sensitivity of melanoma cells to vemurafenib was associated with activation of apoptotic signaling pathway.Conclusion: Targeting of PGK1 may represent a novel strategy of sensitizing melanoma cells to vemurafinib.

Key words: melanoma, PGK1, vemurafenib, apoptosis

LIU Rong, WAN Xin, WANG Xi, LI Fan-lu, JING Jia-ni, CUI Xiang-li. Silencing of PKG1 expression enhances the efficacy of vemurafenib against melanoma cell[J]. CJAP, 2017, 33(4): 289-293.

References

[1] Hagen B, Trinh VA. Managing side effects of vemurafenib therapy for advanced melanoma[J]. J Adv Pract Oncol, 2014, 5(6):400-410.
[2] Niezgoda A, Niezgoda P, Czajkowski R. Novel approaches to treatment of advanced melanoma:a review on targeted therapy and immunotherapy[J]. Biomed Res Int, 2015, 2015:851387.
[3] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016[J]. CA Cancer J Clin, 2016, 66(1):7-30.
[4] Rochette PJ, Lacoste S, Therrien JP, et al. Influence of cytosine methylation on ultraviolet-induced cyclobutane pyrimidine dimer formation in genomic DNA[J]. Mutat Res, 2009, 665(1-2):7-13.
[5] Howard LK, Janice MM. Melanoma.Cancer Treatment and Research, 2016.
[6] Schadendorf D, Fisher DE, Garbe C, et al. Melanoma[J]. Nature Reviews Disease Primers, 2015, 1:1-20.
[7] Manzano JL, Layos L, Bugés C, et al. Resistant mechanisms to BRAF inhibitors in melanoma[J]. Ann Transl Med, 2016, 4(12):237-246.
[8] Demirsoy S, Martin S, Maes H, et al. Adapt, recycle, and move on:proteostasis and trafficking mechanisms in melanoma[J]. Front Oncol, 2016, 6:240.
[9] Shelledy L, Roman D. Vemurafenib:First-in-Class BRAF-mutated inhibitor for the treatment of unresectable or metastatic melanoma[J]. J Adv Pract Oncol, 2015, 6(4):361-365.
[10] Li X, Zheng Y, Lu Z. PGK1 is a new member of the protein kinome. Cell Cycle, 2016, 15(14):1803-1804.
[11] Wang S, Jiang B, Zhang T, et al. Insulin and mTOR pathway regulate HDAC3-mediated deacetylation and activation of PGK1[J]. Plos Biol, 2015, 13(9):el002243.
[12] Li X, Jiang Y, Meisenhelder J, et al. Mitochondria-translocated PGK1 functions as a protein kinase to coordinate glycolysis and the TCA cycle in tumorigenesis[J]. Mol Cell, 2016, 61(5):705-719.
[13] Ai J, Huang H, Lv X, et al. FLNA and PGK1 are two potential markers for progression in hepatocellular carcinoma[J]. Cell Physiol Biochem, 2011, 27(3-4):207-216.
[14] Sun S, Liang X, Zhang X, et al. Phosphoglycerate kinase-1 is a predictor of poor survival and a novel prognostic biomarker of chemoresistance to paclitaxel treatment in breast cancer[J]. Br J Cancer, 2015, 112(8):1332-1339.
[15] Ahmad SS, Glatzle J, Bajaeifer K, et al. Phosphoglycerate kinase 1 as a promoter of metastasis in colon cancer[J]. Int J Oncol, 2013, 43(2):586-590.
[16] Wang H, Zhang L, Yang L, et al. Targeting macrophage anti-tumor activity to suppress melanoma progression[J]. Oncotarget, 2017, 8(11):18486-18496.
[17] Ratterman M, Hallmeyer S, Richards J. Sequencing of new and old therapies for metastatic melanoma[J]. Curr Treat Options Oncol, 2016, 17(10):52-61.
[18] Keating GM. Cobimetinib plus vemurafenib:a review in BRAF (V600) mutation-positive unresectable or metastatic melanoma[J]. Drugs, 2016, 76(5):605-615.
[19] de Golian E, Kwong BY, Swetter SM, et al. Erratum to:Cutaneous complications of targeted melanoma therapy[J]. Curr Treat Options Oncol, 2016, 17(11):57-70.
[20] 李秀娟, 李玉珍, 金春亭, 等. 姜黄素作用PTEN/PI3K/AKT通路诱导食管癌EC109细胞凋亡[J]. 中国应用生理学杂志, 2015, 31(2):174-177.
[21] 周开宇, 吉海龙, 史鹏飞. 苦参碱对体外人髓母细胞瘤D341细胞凋亡、增殖及凋亡相关蛋白的影响[J]. 中国应用生理学杂志, 2016, 32(1):74-77.]